Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety.
about
Ceramide kinase is a mediator of calcium-dependent degranulation in mast cellsThe roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection.Drug safety in the treatment of Crohn's disease.Drug safety in Crohn's disease therapy.Pharmacogenetics of Crohn's disease.Anti-TNFα therapy for chronic inflammatory disease in kidney transplant recipients: Clinical outcomesUpdate on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel diseaseSystematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, biological and epidemiological factors influencing drug repositioning.Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease.Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry.Murine TNF(DeltaARE) Crohn's disease model displays diminished expression of intestinal Ca2+ transporters.
P2860
Q28242923-1D0B2F17-87EE-4980-B219-07379A6CE593Q34623572-9EC5A234-D5A9-4CFC-89BB-4606AA1E211DQ36041692-FD301CB2-1DC2-42EA-9D6B-A7B78FFFBBFCQ37073426-42F116AB-E7AC-458C-9302-72155BE26496Q37205946-2055F63F-7EF4-411D-8729-11F0E9EC5186Q37354812-C0C511F1-F2D3-4847-A1E8-8B7F678F3B25Q38660544-D0A020CA-C8B9-4C26-B203-58872C7CDF5DQ38960040-7A190B90-F338-4400-8CCC-46D71FF427F9Q40524189-2D8FA8E7-AAF8-42EA-9F0D-0CDD8800F1C8Q43778384-27FFE796-E2FA-4F88-BB51-58698F25AC7BQ46760318-6373FCB9-0BDA-4447-B827-B246606BC1CF
P2860
Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Azathioprine and anti-TNF alph ...... clinical efficacy and safety.
@en
type
label
Azathioprine and anti-TNF alph ...... clinical efficacy and safety.
@en
prefLabel
Azathioprine and anti-TNF alph ...... clinical efficacy and safety.
@en
P2093
P1476
Azathioprine and anti-TNF alph ...... clinical efficacy and safety.
@en
P2093
David Watts
Ian D R Arnott
Jack Satsangi
P356
10.1016/S1043-6618(02)00264-5
P577
2003-01-01T00:00:00Z